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1. Introduction
Colorectal cancer is the second most prevalent malignancy 
in Europe (1). In 2013 in Serbia the estimated new cases 
of colorectal cancer were 3900, making it the second 
most frequent malignant tumor in the country (2). The 
expression of E-cadherin, carcinoembryonic antigen 
(mCEA), cyclin B1, erythropoietin (EPO), EPO receptor 
(EPOR), and vascular endothelial growth factor (VEGF) 
indicate the presence, extent, and response to therapy of 
this neoplasm and define the survival period (3,4). mCEA 
is one of the most extensively studied tumor markers in 
colon cancers. During the early stage of colorectal cancer 
mCEA has a low sensitivity and expression; it becomes 
more prominent during the process of tumor development 
(4). E-cadherin belongs to a family of transmembrane 
glycoproteins involved in the mediation of calcium-
dependent cell-cell adhesion in epithelial tissues (5). 
Previous studies have shown a fundamental association 
between downregulation of E-cadherin expression in 
tumor cells and the progression of an invasive tumor 
(6). According to previous results, there is a negative 
correlation between the level of E-cadherin expression and 
tumor grade (7–9). 
EPOR is highly expressed in endothelial cells, neurons, 
the uterus, and various solid tumors (10). EPO and EPOR 
have a significant role in the process of neoangiogenesis, 
stimulating survival of hypoxic cancer cells and tumor 
growth (11). It has been shown that EPO and EPOR 
expressions are more prominent in adenocarcinoma of the 
colon than in mucinous carcinomas; they are also more 
prominent in moderately differentiated carcinomas than 
in poorly differentiated ones (12,13). Besides EPO and 
EPOR, VEGF is considered one of the most important 
angiogenic agents overexpressed in colon adenocarcinoma 
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(14). In addition to tumor tissues, VEGF is expressed in 
noncancerous colonic tissue (14,15). 
Cyclin B1 belongs to the cyclin family of proteins 
involved in the control of normal cell proliferation (16). 
Cyclin B1 is the component of the maturation/mitosis-
promoting factor with an important role in the G2–M 
transition (16,17). Cyclin B1 expression is irregular with 
minimal expression in the G1 phase, and maximal at the 
G2–M transition, which results in early entry into mitosis, 
uncontrolled cell proliferation, and tumor growth (16,17). 
Previous studies reported that cyclin B1 was detected in 
breast, prostate, colon, and oral cancers; high levels of its 
expression are associated with poor survival of patients 
(18,19). 
The aim of our study was to investigate the 
immunohistochemical expression of E-cadherin, mCEA, 
cyclin B1, VEGF, EPO, and EPOR in adenocarcinoma of the 
colon and their correlation with basic clinicopathological 
characteristics. In addition to protein studies of angiogenic 
factors EPOR and VEGF, we also performed their 
gene expression studies concomitantly in cancer and 
neighboring healthy tissues. Using this approach, we 
wanted to shed light on the proliferation, differentiation, 
and angiogenesis markers in adenocarcinoma of the colon 
as potential diagnostic and prognostic factors. 
2. Materials and methods
2.1. Subjects 
The present study was performed in accordance with the 
regulations of the local ethics committee. We included 
38 patients with adenocarcinoma of the colon who 
underwent surgery. We also included 10 controls for 
immunohistochemistry and 38 control samples for RT-
PCR. 
2.2. Immunohistochemical procedure
The examined tumor tissue specimens were fixed in 
10% buffered (PBS) formalin and embedded in paraffin. 
Tissue blocks of the tumor (five tissue sections of each 
paraffin block) were transversely cut in 5-µm-thick 
serial sections. Five consecutive sections from each 
level, taken at intervals of 20–50 µm, were stained with 
different antibodies. For immunohistochemical analysis, 
polyclonal and monoclonal antibodies against mCEA 
(monoclonal mouse anti-human antibody, Novocastra, 
Leica Biosystems Ltd, Clone: 12–140-10), E-cadherin 
(monoclonal mouse anti-human antibody, Dako, LOT 
NO: 00023), cyclin B1 (monoclonal mouse anti-human 
antibody, Dako, LOT NO: 098), EPOR (rabbit polyclonal 
anti-mouse antibody, Santa Cruz Biotechnology, LOT NO: 
D1210), VEGF (BD Pharmingen, cat. no. 555036, dilution 
1:1000) were used. The tissue samples were fixed in 10% 
buffered formalin solution and embedded in paraffin. The 
tissue sections were cut at 5 µm, heated at 56 °C for 60 
min, then deparaffinized and rehydrated through a series 
of xylenes and alcohols, followed by an epitope retrieval 
step. Tissue sections were treated with 3% H2O2 solution in 
PBS to block endogenous peroxidase activity. Then tissue 
sections of colon cancer and control tissues were heated 
in a microwave oven (at 680 W, in 10 mmol/L citrate 
buffer with a pH of 6.0 for 21 min) for epitope retrieval. 
The next step was incubation of tissue sections with 
appropriate antibodies (against mCEA, E-cadherin, cyclin 
B1, VEGF, and EPOR) in a humid chamber for 60 min 
at room temperature. Immunostaining was performed 
using the streptavidin–biotin technique (LSAB+/HRP 
Kit, Peroxidase Labeling, K0690, DakoCytomation). The 
immunoreactivity complex was visualized with Dako 
Liquid DAB + Substrate/Chromogen System (Code No. 
K 3468) and counterstained with Mayer’s hematoxylin 
(Merck). Tumor tissue sections with omitted primary 
antibody were used as negative controls. Tumor tissue 
sections known to express mCEA, E-cadherin, cyclin 
B1, and EPOR were used as positive controls for 
immunohistochemical staining. 
2.3. Scoring system
EPOR and mCEA expressions of 0 and 2 grades and 
E-cadherin expression of 0 and 1 grades were considered 
negative expression, while in other cases the expression 
of those three markers was considered positive. Tissue 
samples for EPOR, mCEA, and E-cadherin were scored on 
a scale representing the estimated proportion and intensity 
of positive-staining tumor cells (with a range of 0–6). The 
scores for EPOR, mCEA, and E-cadherin were determined 
by adding intensity for the immunoreactivity staining 
of tumor cells (0, none; 1, weak; 2, intermediate; and 3, 
strong) and the average number of staining tumor cells. The 
number of cyclin B1 immunoreactive cells was determined 
in the surface and glandular epithelium using a computer-
supported imaging system connected to a light microscope 
(Olympus AX70) with objective magnification of 40×. The 
intensity of the cyclin B1 immunostaining was evaluated 
by dividing staining reactions in three score groups: 0: 
no immunostaining cells; 1: weak to moderate staining 
intensity in 1% to 50% of tumor cells; 2: strong staining 
intensity in >50% of tumor cells. Immunoreactivity for 
VEGF expression was evaluated according to the degree of 
staining, with staining intensities scored as: 0, no positive 
staining cells; 1, less than 10% of cells stained; 2, 11% to 
50% of cells stained; 3, more than 50% of cells stained. 
The group of patients with positive VEGF expression was 
defined by observation of staining of more than 10% of the 
tumor area (scores 2 and 3). 
2.4. Real-time PCR
We used the RNeasy protocol for the isolation of total 
RNA from 38 tumors and 38 healthy tissues according 
to the manufacturer’s instructions (Qiagen GmbH). 
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Concentration and integrity of total RNA was assessed 
using Ultrospec 3300 spectrophotometer (Amersham 
Pharmacia). Equal amounts of RNA from different 
samples were transcribed into cDNA using the Maxima 
First Strand cDNA Synthesis kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. Quantitative 
real-time PCR analyses were performed using a 4800 Light 
Cycler (Roche) and Taqman oligonucleotides probes for 
VEGF. The oligonucleotides probe 5’ CCA AGT GGT 
CCC AGG CTG CAC C 3’ was fluorescently labeled on 
the 5’ end with 6-carboxy-fluorescein and on the 3` end 
with 6-carboxy-tetramethyl-rhodamine. VEGF primers 
were: forward 5’ TTG CTG CTC TAC CTC CAC CAT 3’ 
and reverse 5’ CAC TTC GTG ATG ATT CTG CCC 3’. 
PCR reaction conditions consisted of 50 °C for 2 min and 
95 °C for 4 min, followed by cycling between a melting 
temperature of 95 °C for 15 s and an anneal-extension 
temperature of 60 °C for 1 min, repeated for 40 cycles. 
Quantification of the corresponding mRNA transcript 
was determined by comparison with VEGF specific cDNA 
standards. β-Actin was used as an internal control for the 
total amount of RNA analyzed. 
2.5. Statistical analysis
The results are expressed as means ± standard deviation 
(SD). Values were compared using independent samples 
t-tests with SPSS 19 for Windows. P < 0.05 was considered 
significant. 
3. Results
3.1. Clinicopathological parameters and correlation with 
biological markers
The ages of patients ranged from 54 to 86 years (mean 
± SD, 72.8 ± 8 years). The tumor size ranged between 1.5 
and 10 cm, and the histological grades were G1, G2, and 
G3 in 18.4% (7/38), 76.3% (29/38), and 5.3% (2/38) of 
patients, respectively. In 23 patients (60.6%) lymph node 
status was negative, while positive lymph node status was 
detected in 15 patients (39.4%). Distant metastasis was 
found in only 1 (2.6%) patient (Table 1). Statistical analyses 
showed a significant positive correlation between tumor 
size and positive lymph node status (r = 0.483, P < 0.01), 
and between tumor size and histological tumor grade (r 
= 0.342, P < 0.05, Table 2). Significant positive correlation 
was also found between tumor size and cyclin B1 tumor 
expression (r = 0.414, P < 0.01, Table 2) and between 
E-cadherin and mCEA expression (r = 0.409, P < 0.05, 
Table 2). Significant negative correlation was detected 
between VEGF protein expression and lymph node status 
(r = –0.329, P < 0.05, Table 2). 
3.2. E-cadherin, mCEA, and cyclin B1 immunoexpression
Positive E-cadherin protein expression in tumors was 
detected in 30 patients (78.9%) and in all 10 controls 
(10/10, 100%, Table 3). In our study group the highest 
level of E-cadherin expression, with scores of 5 and 6, was 
detected in 17 patients (17/38, 44.7%, Table 3); moderate 
level of expression (4) was found in 9 (9/38, 23.7%) 
patients; and low level of expression (3) was detected in 4 
patients (4/38, 10.5%, Table 3). Statistical analysis showed 
significant differences in E-cadherin expression between 
tumor and control samples (F = 4.257, P < 0.05, Figure 1). 
High level of positive expression (5 and 6) for mCEA was 
detected in 29 patients (29/38, 76.3%), while minimum 
level of positive expression was detected in 3 patients 
Table 1. Clinicopathological characteristic of adenocarcinoma of 
the colon.
Clinicopathological 
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(3/38, 7.9%, Table 3, Figure 2). Moderate level (4) of mCEA 
expression was detected in 6 patients (6/38, 15.8%, Table 
3). Statistical analysis did not show that mCEA expression 
was significantly higher in tumor samples compared with 
control patients (Figure 1). Positive expression of cyclin B1 
in more than 50% of tumor cells was detected only in 6 
tumor samples (6/38, 15.8%), while in 32 patients (32/38, 
84.2%) the number of cyclin B1 positive cells was less than 
50% (Table 3). In all 10 control cases the average number 
of cyclin B1 positive cells was less than 30% (Table 3). 
Statistical analysis showed significant differences in cyclin 
B1 nucleus accumulation between tumor and control 
tissues (F = 7.716, P < 0.05, Figure 1). Namely, cyclin 
B1 expression was significantly higher in tumor than in 
control samples (Figures 1 and 2). 
3.3. VEGF and EPOR gene and protein expressions in 
adenocarcinoma of the colon
Negative expression of EPOR was detected in 26 tumor 
samples (26/38, 68.4%), while maximal positive expression, 
scored as 6, was detected in 4 patients (4/38, 10.5%, Table 
3). In control samples positive EPOR expression was 
detected in 7 samples (7/10, 70%, Table 3). Similar to the 
results for cyclin B1, statistical analysis showed significant 
differences in EPOR expression between tumor and 
control patients (P < 0.05, Figures 1 and 2). VEGF positive 
protein expression was detected in 35 tumor tissue 
samples (35/38, 92.1%, Table 3). Eight control samples 
were negative for VEGF protein expression and had a 
score of 1 (8/10, 80%, Table 3). The VEGF protein levels 
were significantly higher in tumor samples than in control 
samples (Figure 2). Statistical analysis showed that VEGF 
gene expression was significantly higher in tumor than in 
control samples (Figure 3). In contrast, EPO and EPOR 
genes were expressed only in traces in tumor and control 
samples (not shown). 
4. Discussion
The presented findings showed that cyclin B1, EPOR, and 
VEGF gene and protein expressions were significantly 
higher in tumor than in control samples, while 
E-cadherin expression was significantly decreased in 
tumor samples, accompanied by positive correlation with 
mCEA. Significant positive correlation characterized the 
relationship between tumor size and cyclin B1 and that 
between tumor grade and lymph node status. Positive 
correlation was also observed between E-cadherin and 
mCEA expression. Cyclin B1 and VEGF gene and protein 
expressions were significantly increased in tumor samples 
in comparison with their expressions in control patients. 
The main role of E-cadherin in the process of normal 
tissue development was verified with the appearance of 
lethality in E-cadherin gene knockout mice at an early 
stage during embryogenesis (20). Dysregulation of 
E-cadherin expression was essential in the development 
of neoplastic tissue, normal growth, loss of differentiation, 
and increased cell proliferation related to invasive 
behavior (6). It was shown that invasive behavior and the 
appearance of metastasis in breast and bladder cancer 
Table 2. Correlation between E-cadherin, mCEA, EPOR, cyclin B1, VEGF gene and VEGF protein expressions, and clinicopathological 
characteristics.






node status Grade Metastasis Age
E-cadherin 1 0.409* –0.195 –0.062 –0.112 –0.118 –0.078 –0.203 0.164 –0.038 –0.184
mCEA 0.409* 1 –0.115 0.041 –0.071 –0.231 0.000 0.000 0.111 –0.211 0.049
Cyclin B1 –0.195 –0.115 1 –0.034 0.054 –0.071 0.414** 0.191 0.275 0.247 –0.048
EPOR –0.062 0.041 –0.034 1 –0.164 –0.195 –0.107 –0.056 –0.291 0.077 0.201
VEGF gene –0.112 –0.071 0.054 –0.164 1 –0.245 –0.245 –0.079 0.019 0.142 0.003
VEGF IHC –0.118 –0.231 –0.071 –0.195 –0.245 1 –0.180 –0.33* –0.085 0.108 –0.081
Tumor size –0.078 0.000 0.414** –0.107 –0.245 –0.180 1 0.483** 0.342* 0.098 –0.053
Lymph node status –0.203 0.000 0.191 –0.056 –0.079 –0.33* 0.483** 1 0.112 0.204 0.015
Grade 0.164 0.111 0.275 –0.291 0.019 –0.085 0.342* 0.112 1 0.046 0.034
Metastases –0.038 –0.211 0.247 0.077 0.142 0.108 0.098 0.204 0.046 1 0.119
Age –0.184 0.049 –0.048 0.201 0.003 –0.081 –0.053 0.015 0.034 0.119 1
Values in bold are significant: * P ≤ 0.05; ** P ≤ 0.01. 
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Table 3. E-cadherin, mCEA, cyclin B1, VEGF, and EPOR expression in tumors and controls.
E-cadherin expression in tumors E-cadherin expression in controls
0 5 (13.2%) 0
2 3 (7.9%) 0
3 4 (10.5%) 1 (10%)
4 9 (23.7%) 0
5 6 (15.8%) 3 (30%)
6 11 (28.9%) 6 (60%)






mCEA expression in tumors mCEA expression in controls
0 0 0
2 0 0
3 3 (7.9%) 0
4 6 (15.8%) 4 (40%)
5 10 (26.3%) 4 (40%)
6 19 (50%) 2 (20%)






EPOR expression in tumors EPOR expression in controls
0 16 (42.2%) 0
2 10 (26.3%) 3 (30%)
3 4 (10.5%) 2 (20%)
4 3 (7.9%) 0
5 1 (2.6%) 2 (20%)
6 4 (10.5%) 3 (30%)






Cyclin B1 expression in tumors Cyclin B1 expression in controls
≤50% 32 (84.2%) 10 (100%)
>50% 6 (15.8%) 0
VEGF expression in tumors VEGF expression in controls
0 0 0
1 3 (7.9%) 8/10 (80%)
2 20 (52.6%) 2/10 (80%)
3 15 (39.5%) 0
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were associated with decreased expression of E-cadherin 
(21,22). Our results are in agreement with these studies 
because E-cadherin levels were significantly higher in 
healthy controls than in tumor samples. 
The mCEA levels in the serum of patients with 
colorectal, gastric, pancreatic, lung, and breast carcinoma 
were increased compared with those in the serum of 
healthy controls (23). In the same study it was confirmed 
that increased levels of serum mCEA showed 100% 
sensitivity in differentiating metastatic liver disease from 
colorectal cancer. Our results also demonstrated that 
mCEA expression was higher in tumor samples than in 
control ones. Moreover, serum concentrations of mCEA 
were higher in patients with well-differentiated tumors 
than in patients with poorly differentiated colon cancers 
(24). Our results showed a positive, but not significant, 
correlation between mCEA and tumor grade. 
During the process of tumor growth, the lack of blood 
supply created a hypoxic environment that induced the 
release of hypoxia inducible factor-1 (HIF-1) to stimulate 
angiogenesis by activating VEGF expression (25,26). Two 
studies confirmed that high levels of VEGF expression 
indicated poor prognosis in patients with colorectal cancer, 
invasive tumor behavior with increased rates of vascular-
lymphatic and lymph node metastasis, and increased 
incidence of distant metastasis (27,28). The results of the 
present study also confirmed significantly higher levels of 
VEGF gene and protein expressions in tumor samples of 
colon adenocarcinoma than in control samples. 
EPO and EPOR are expressed in numerous normal 
nonhematopoietic cells as well as in cancer tissues, 
especially at the surface of endothelial cells and various 
solid tumors (10,12). EPO, EPOR, and VEGF play a key 
role in the process of neoangiogenesis, supporting survival 
of hypoxic cancer cells and tumor growth. Lee et al. (29) 
showed that higher expression of VEGF and EPO were 
associated with resistance to treatment, increased tumor 
aggressiveness, and poor prognosis in patients with cancer. 
In our study EPOR protein expression was significantly 
higher in tumor samples than in control ones, but EPO 
gene expression was found only in traces. This could be 
related to the small invasiveness of the tumor and the 
absence of a hypoxic state. 
Despite significant progress, the role of E-cadherin, 
mCEA, cyclin B1, and VEGF in colorectal cancer cells 
remains unclear, especially in association with EPO and 
EPOR expression. This is the first immunohistochemical 
study to report E-cadherin, mCEA, cyclin B1, VEGF, 
and EPOR expressions and their correlations with 
clinicopathological factors in colorectal adenocarcinoma. 
The present findings showed that cyclin B1 and VEGF 
expressions were significantly elevated in tumor samples, 
and E-cadherin expression was significantly decreased in 
tumor samples and positively correlated with mCEA. A 
significant positive correlation was found between cyclin 
B1 and tumor size, tumor size and grade, and tumor size 
and lymph node status. Since our study was carried out 
for 1 year, we could not reach a conclusion about the 
prognostic significance of the studied markers. However, 
decreased expression of EPO and EPOR, increased VEGF 
and cyclin B1 expression, and predominant moderate 
differentiation of the tumor could suggest a low level of 
aggressiveness, good prognosis, and long period of patient 
survival. Observation of the same patient population for 
an extended period could give valuable information about 


















Figure 1. Immunohistochemical expression of E-cadherin, 
mCEA, cyclin B1, VEGF, and EPOR in colorectal adenocarcinoma 
and controls. Control vs. adenocarcinoma of the colon: a) 
E-cadherin (P < 0.05); b) Cyclin B1 (P < 0.05); c) EPOR (P < 
0.05); d) VEGF (P < 0.01).
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Figure 2. Specific pattern of immunohistochemical expression of E-cadherin, mCEA, cyclin B1, VEGF, and EPOR in colorectal adenocarcinoma 
and controls. Note the strong membranous deposition of E-cadherin in control cells (a) in contrast to colorectal cancer cells (b). mCEA showed 
strong immunoreactivity in colorectal cancer cells (d) in comparison with control cells (c). Cyclin B1 expressed significantly higher in colorectal 
cancer cells (f) in comparison with control cells (e). EPOR showed moderate membranous and partly perinuclear staining in colorectal cancer 
cells (h) in comparison with its decreased expression in control cells (g). VEGF immunoreactivity was significantly higher in tumor cells (j) in 
comparison with control tissue sections (i). Magnification: 20× (a, b, c, d, g, h, i, and j); 40× (e and f). 
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Figure 3. VEGF gene expression in colorectal adenocarcinoma 
tissue samples and neighboring healthy tissues (controls). Tumor 
samples vs. controls: * P < 0.05. 
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